Get access

Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature

Authors


  • Conflict of interest: none.

Verónica López, MD
Departments of Dermatology
Hospital Clínico Universitario de Valencia
Avda. Blasco Ibáñez, nº 17
46010 Valencia
Spain
E-mail: veronica_17@live.com

Abstract

Sarcoidosis is a multisystem granulomatous disease that affects multiple organs in adults between 20 and 50 years old. Interferon alpha (IFN-α) is an immunomodulator that has been used in a wide range of diseases, including hepatitis C virus infection, multiple sclerosis, and other types of neoplasias, including leukemia, lymphoma, Kaposi’s sarcoma, and melanoma. Standard IFN-α-induced sarcoidosis has been reported, but there are few reports of cutaneous sarcoidosis with pegylated IFN-α therapy. We present a new case of cutaneous sarcoidosis after treatment with pegylated IFN, and a review of the literature.

Get access to the full text of this article

Ancillary